Table 1 Patient characteristics for the overall study population
All patients |  | Male (N = 98) | Female (N = 63) | Total (N = 161) | p value |
|---|---|---|---|---|---|
Age | Median (Q1, Q3) | 72.0 (63.2, 77.0) | 67.0 (60.0, 74.5) | 71.0 (62.0, 77.0) | 0.1590 |
Diagnosis | NSCLC | 45 (45.9%) | 24 (38.1%) | 69 (42.9%) | 0.3280 |
| Â | Melanoma | 53 (54.1%) | 39 (61.9%) | 92 (57.1%) | Â |
ECOG Performance Status | N-Miss | 0 | 1 | 1 | Â |
| Â | 0 | 52 (53.1%) | 33 (53.2%) | 85 (53.1%) | 0.9400 |
| Â | 1 | 40 (40.8%) | 26 (41.9%) | 66 (41.2%) | Â |
| Â | 2 | 6 (6.1%) | 3 (4.8%) | 9 (5.6%) | Â |
Prior systemic treatment | N-Miss | 0 | 1 | 1 | Â |
| Â | No | 84 (85.7%) | 51 (82.3%) | 135 (84.4%) | 0.5570 |
| Â | Yes | 14 (14.3%) | 11 (17.7%) | 25 (15.6%) | Â |
Current stage | N-Miss | 2 | 0 | 2 | Â |
| Â | III | 11 (11.5%) | 7 (11.1%) | 18 (11.3%) | 0.9460 |
| Â | IV | 85 (88.5%) | 56 (88.9%) | 141 (88.7%) | Â |
Treatment | Nivolumab | 46 (46.9%) | 33 (52.4%) | 79 (49.1%) | 0.4670 |
| Â | Pembrolizumab | 30 (30.6%) | 22 (34.9%) | 52 (32.3%) | Â |
| Â | Atezolizumab | 4 (4.1%) | 2 (3.2%) | 6 (3.7%) | Â |
| Â | Chemo-immuno | 18 (18.4%) | 6 (9.5%) | 24 (14.9%) | Â |
RECIST | CR | 8 (8.2%) | 4 (6.3%) | 12 (7.5%) | 0.3010 |
| Â | PR | 34 (34.7%) | 14 (22.2%) | 48 (29.8%) | Â |
| Â | SD | 21 (21.4%) | 19 (30.2%) | 40 (24.8%) | Â |
| Â | PD | 35 (35.7%) | 26 (41.3%) | 61 (37.9%) | Â |
Progression of disease | No | 33 (33.7%) | 18 (28.6%) | 51 (31.7%) | 0.4970 |
| Â | Yes | 65 (66.3%) | 45 (71.4%) | 110 (68.3%) | Â |
Progression free survival (months) | Median (95%CI) | 7.6 (6.1,12.5) | 8.1 (3.3,10.6) | 8.1 (6.1,9.8) | 0.9826 |
Status | Alive | 41 (41.8%) | 28 (44.4%) | 69 (42.9%) | 0.7440 |
| Â | Death | 57 (58.2%) | 35 (55.6%) | 92 (57.1%) | Â |
Overall survival (months) | Median (95%CI) | 13.9 (9.9,23.5) | 18.9 (9.5,22.6) | 16.7 (11.4,21.6) | 0.6118 |
Follow-up | Median (Q1, Q3) | 23.1 (17.4,29.4) | 21.8 (16.8,27.6) | 23.0 (17.4,27.8) | Â |